April 8, 2019
Janssen Pharmaceutical said on April 6 that it has filed in Japan its anti-CD38 monoclonal antibody Darzalex (daratumumab) in combination with lenalidomide and dexamethasone for an additional indication of multiple myeloma including treatment-naïve patients. Progression-free survival (PFS) of Darzalex in...read more